FBIO
(NASDAQ)
1.84
+0.000000  (+0)
Volume (24h): 215.58K Day Range: 1.80 - 1.92
Market Cap: 144.36M 52W Range: 1.09 - 3.11
Mar-30-20 11:30AM Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate HighlightsGlobeNewswire
Mar-23-20 01:20PM Fortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase ProgramGlobeNewswire
Mar-18-20 10:39AM Analysts Are Upgrading Fortress Biotech, Inc. After Its Latest ResultsSimply Wall St.
Mar-16-20 08:45PM Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate HighlightsGlobeNewswire
Mar-11-20 08:15PM Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate HighlightsGlobeNewswire
Feb-24-20 01:00PM Fortress Biotech Announces Closing of Series A Preferred Stock Offering and Full Exercise of Over-Allotment OptionGlobeNewswire
Feb-18-20 01:00PM Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106GlobeNewswire
Feb-13-20 01:00PM Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDAGlobeNewswire
Feb-12-20 01:00AM Fortress Biotech Announces Pricing of Series A Preferred Stock OfferingGlobeNewswire
Jan-22-20 01:30PM Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020GlobeNewswire
Jan-17-20 01:07PM The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect SharesBenzinga
12:23PM Loss-Making Fortress Biotech, Inc. (NASDAQ:FBIO) Expected To BreakevenSimply Wall St.
Jan-16-20 01:30PM Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes DiseaseGlobeNewswire
Jan-13-20 01:15PM Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell CarcinomaGlobeNewswire
12:30PM Journey Medical Corporation Recaps 2019 GrowthGlobeNewswire
Dec-23-19 01:30PM Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS DisordersGlobeNewswire
Dec-16-19 12:28PM Hedge Funds Have Never Been This Bullish On Fortress Biotech Inc (FBIO)Insider Monkey
Dec-11-19 01:30PM Avenue Therapeutics Announces Submission of New Drug Application for IV TramadolGlobeNewswire
Dec-09-19 12:30PM Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined ImmunodeficiencyGlobeNewswire
Dec-07-19 01:35PM The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom RulingBenzinga
Dec-02-19 01:30PM Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx ConferenceGlobeNewswire
Dec-01-19 02:30PM The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And MoreBenzinga
Nov-26-19 01:00AM Fortress Biotech Announces Pricing of Series A Preferred Stock OfferingGlobeNewswire
Nov-20-19 02:20PM Checkpoint Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire
Nov-19-19 09:01PM Checkpoint Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
Nov-14-19 01:30PM Fortress Biotech Ranked in Top 10 of Deloitte’s 2019 Technology Fast 500™GlobeNewswire
Nov-12-19 12:30PM Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate HighlightsGlobeNewswire
Nov-10-19 02:16PM Do Insiders Own Shares In Fortress Biotech, Inc. (NASDAQ:FBIO)?Simply Wall St.
Nov-08-19 12:30PM Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswire
Nov-07-19 09:30PM Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate HighlightsGlobeNewswire
Nov-06-19 02:15PM Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual MeetingGlobeNewswire
Nov-04-19 12:30PM Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate HighlightsGlobeNewswire
Oct-28-19 12:30PM Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug DevelopmentGlobeNewswire
Oct-24-19 12:30PM Fortress Biotech to Participate in the 5th Annual Dawson James Small Cap Growth ConferenceGlobeNewswire
Oct-18-19 12:30PM Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual MeetingGlobeNewswire
Oct-10-19 12:00PM Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant GliomaGlobeNewswire
Sep-30-19 11:30AM Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019GlobeNewswire
Sep-26-19 12:30PM Mustang Bio to Participate in October 2019 Investor ConferencesGlobeNewswire
Sep-23-19 12:30PM Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of HopeGlobeNewswire
Sep-16-19 11:30AM Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology (ESMO) Congress 2019GlobeNewswire
Sep-11-19 05:20PM Investors Who Bought Fortress Biotech (NASDAQ:FBIO) Shares Three Years Ago Are Now Down 24%Simply Wall St.
Sep-09-19 12:00PM Mustang Bio to Present at Scientific Conferences in September 2019GlobeNewswire
Sep-04-19 12:30PM Checkpoint Therapeutics to Present at September 2019 Investor ConferencesGlobeNewswire
Aug-29-19 12:00PM Mustang Bio to Present at September 2019 Investor ConferencesGlobeNewswire
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York..
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)